| Current Price | $151.72 | Mkt Cap | $269.4B |
|---|---|---|---|
| Open | $151.20 | P/E Ratio | 21.65 |
| Prev. Close | $151.72 | Div. (Yield) | $5.64 (3.7%) |
| Daily Range | $149.28 - $152.40 | Volume | 5,994,936 |
| 52-Wk Range | $105.56 - $175.91 | Avg. Daily Vol. | 7,557,946 |
| Current Price | $151.72 | Mkt Cap | $269.4B |
|---|---|---|---|
| Open | $151.20 | P/E Ratio | 21.65 |
| Prev. Close | $151.72 | Div. (Yield) | $5.64 (3.7%) |
| Daily Range | $149.28 - $152.40 | Volume | 5,994,936 |
| 52-Wk Range | $105.56 - $175.91 | Avg. Daily Vol. | 7,557,946 |
The best Bull and Bear pitches based on recency and number of recommendations.
Good new drugs coming on line to replace the profits that came from Humira
This mega-cap has made a big run since Express Scripts's announcement that it will take AbbVie's hep C treatment in lieu of Gilead's. Also, an amazing preponderance of CAPS bulls favor this stock beating the market from here -- very interesting. For… More
Read the most recent pitches from players about ABBV.
Recs
TMFWordman5150
(37.58)
Submitted: 2/17/2022 12:04:57 PM :
Start Price:
$143.78
NYSE:ABBV Score:
+17.24
Earnings Growth; a solid dividend of $5.64 per share; and a Pharma manufact. market with a CAGR of 11.34% through 2028.
Recs
JohnnyCaffeine
(< 20)
Submitted: 1/13/2022 6:48:34 AM :
Start Price:
$133.86
NYSE:ABBV Score:
+30.93
Good new drugs coming on line to replace the profits that came from Humira
Recs
TMFkodyk123
(68.04)
Submitted: 7/26/2021 12:53:49 PM :
Start Price:
$115.32
NYSE:ABBV Score:
+43.09
Despite AbbVie's near-term headwinds relating to the upcoming loss of exclusivity of Humira in the U.S., the company boasts promising drugs in its oncology and immunology segments. Venclexta has 3 different indications that are anticipated to be approved by next year. In addition, the stock appears to be trading at a discount to fair value with an attractive 4.4% dividend yield.
Find the members with the highest scoring picks in ABBV.
cooleyly (57.13) Score: +392.49
The Score Leader is the player with the highest score across all their picks in ABBV.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| armydave | 51.91 |
|
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment | |
| pirotta | < 20 | 1/10/2013 |
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment | |
| deliman723 | 67.21 | 1/10/2013 |
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment | |
| concealedweaponR | < 20 | 1/10/2013 |
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment | |
| drjohn432 | < 20 |
|
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment | |
|
valari25 | 99.64 |
|
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment |
|
|
GW1000 | 85.75 |
|
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment |
|
|
mattmmurphy | 72.24 | 1/10/2013 |
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment |
| cooleyly | 57.13 | 1/10/2013 |
|
5Y | $23.06 | +557.86% | +165.37% | +392.49 | 0 Comment | |
|
|
kinosternon | 98.59 | 1/9/2013 |
|
5Y | $23.17 | +554.87% | +166.60% | +388.27 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
